"Large infusion and raw materials and preparations" three-shot driven Collon Pharmaceutical antibody drug research and development pipeline analysis.

Sichuan Collun Pharmaceutical Co., Ltd(hereinafter referred to as Collum Pharmaceuticals), was founded in 1996, and in June 2010 in the Shenzhen Stock Exchange successfully listed, after more than 20 years of development, Collum Pharmaceuticals has grown into a"big infusion and raw materials and preparations"three-shot driven modern pharmaceutical companies2012, Collum Pharmaceuticals has gradually increased its investment in innovative pharmaceutical research, and now it is beginning to enter the harvest period, with abundant product pipelinesOn May 29,, Collon Pharmaceuticals issued a series of announcements on the implementation of employee equity incentive scheme by subsidiary Sichuan Collon Pharmaceutical Research Co., Ltd., and a series of announcements on the transfer of 10% of the shares of Koren Botai and Collon Pharmaceutical Research to natural persons Wang Jingyi and Related TransactionsFurther strengthen the drive for research and development innovationthis paper, 11 antibody drug research and development pipelines were collatedCollum Pharmaceuticalsof the nine antibody drugs, two are ADC drugs and there are eight different targets,LAG3, TROP-2, TIM-3, VEGFR2, HER2, PD-L1, TPOR, EGFRincludes bothClassic immunological checkpoints such as PD-L1also contain new targets such asTROP-21
LAG-3
LAG-3, encoded by the LAG-3 gene, mainly expressed in activated T cells, NK cells, and plasma cell-like dendritic, cell surface molecular proteins with T-cell functional regulation, was discovered in 1990 The main ligand of LAG-3 is MHCII, which negatively regulates the proliferation and activation of T cells in a similar way to CTLA-4 and PD-1, and has also shown that it plays a role in inhibiting regulatory T-cell function and maintains the role of CD8T cells in a tolerable state Preclinical studies have shown that inhibition of LAG-3 can restore cytotoxicity to T cells, thereby limiting tumor growth and becoming a target for cancer immunotherapy in many pharmaceutical companies pharmaceutical giants Novartis, BMS, Mercado, GSK, Sanofi, BI
and so on are in the layout, BMS alone launched more than 20 LAG-3-target clinical trials, and the domestic Hengrui, Cinda, Yiteng, Reding, Collon have carried out relevant research The research and development of LAG-3 immunotherapy Source: BioSeedin Bos
May 22, 2020, the clinical application of the LAG-3 antibody KL-A289 of Collum Pharmaceuticals/Anyuan Pharmaceuticals was accepted by NMPA as the 5th domestic LAG-3 antibody The single resistance blocks both the ligandMHC-II and FGL-1 2 TROP-2
TROP-2, emerging target treatment sites for tumors, highly expressed in various human epithelial cancers, is related to the occurrence, invasion and metastasis of malignant tumors On April 22, 2020, the U.S FDA has accelerated the approval of Immunomedics' ADC drug IMMU-132 for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) This makes Trodelvy the first FDA-approved antibody to mate antibody to treat mTNBC patients with the TARGET TROP-2 antigen It is also the world's first antibody coupling drug to target TROP-2 approved by regulators TROP2 promotes tumor immersion and metastasis Source: Drug Mingcon
domestic Biota, Colum, polyjute have been conducted or approved to carry out targeted TROP2 monoantidrug clinical trials 3 TIM-3 TIM-
3, is a class of T-cell surface inhibitors that can cause the failure of T-cells during cancer and chronic viral infections, the same as CTLA-4, PD-1 source: Biopharmaceutical small-
TIM-3 is currently one of the most studied immunotherapy targets, but there are no domestic and foreign drugs, BMS, Novartis, GSK in the clinical stage of Phase 2 The domestic Hengrui, Koren, Baiji Shenzhou is in the stage of Phase 1 clinical trials, Zhikang Hongyi, Fu Honghanyu, Van Enshi, Zhao Derivatives, Zhiren Meibo, Lizhu Monodyagain and so on are in the pre-clinical stage 3 VEGFR2 VEGFR2, VEGF is a growth factor that acts specifically on vascular endothelial cells, directly involved in inducing tumor angiogenesis, and is closely related to tumor growth, invasion and metastasis, And Lilly developed Remo remoremonotag by targeting the suppression of VEGF receptor VEGFR2 to block the effect of VEGF on tumor there are more companies in China that have developed remorezumagen biosimilars in China, and Colum began clinical trials in 2017 4
HER-2
HER-2, also known as ERBB2, CD340, etc., belongs to the epidermal growth factor receptor (EGFR) family of four members Overexpression or abnormal activation of HER2 can lead to malignant proliferation of cells and participation in the occurrence and progression of cancer As early as the 1980s, the analysis of clinical samples found that the overexpression of HER2 was positively associated with the degree of malignancy of breast cancer A large number of subsequent basic studies have demonstrated the promotering of HER2 in the proliferation of breast cancer cells and other types of cancer cells quralum monotonica is the world's first humanized monoclonal antibody drug targeting the HER-2 protein, developed by Genentech The mechanism of queraloid anti-tumor includes direct suppression of HER2-mediated signaling pathways to inhibit cell growth and cell toxicaction (ADCC) mediated by NK cells to kill cancer cells by inherent immune cells such as FC segment source: the of pharmaceutical melting circle at home and abroad in the study of HER-2-ADC drugs more, including domestic Hundred Otai, Collum, Rongchang Bio, Zhejiang Pharmaceuticals, Hengrui, Baiji Shenzhou and so on have been carried out clinical trials, of which Bai-Atai the fastest progress, has begun phase 3 clinical trials 5
PD-L1
PD-1, procedural death receptor 1, is a protein expressed on immune cell T cells to identify and "kill" tumor cells PD-L1, procedural death receptor-ligand 1, is the protein expressed on tumor cells, PD-L1 will bind specifically to PD-1, and when combined, it inhibits the activation and proliferation of T cells, resulting in the escape of tumor cells PD-1/PD-L1-based immunoothestinhibitors have successfully developed and marketed a number of cellular immunotherapy drugs, saving countless cancer patients, and immunological immunotherapy based on immunoosis has won the 2018 Nobel Prize in Physiology or Medicine as one of the most famous immunological checkpoints (one), PD-L1 research and development of the hot test since needless to say, as of the beginning of 2020, the domestic has accumulated 51 PD-1/PD-L1 antibodies, of which PD-L1 monoantiphoresis 19, PD-1 monoantiphoresis 23, double resistance 9 6 TPOR A157, is a biosimilar to the second-line drug Romistin, a second-line drug developed by Amgen, which is a platelet-producing receptor (TPOR) agonisant that effectively relieves persistent or chronic immune platelet reduction in children immune platelet reduction disorder (ITP) is a common epigenetic haemorrhagic disease, clinically itP first line using glucocorticoids or injectionglobulin and other ways, but osteoporosis and other side effects are larger, and more than half of patients will be ineffective treatment or will recur, 40% of patients will be transferred to second-line ITP medication currently listed on the global listed a total of four immunoplatelet reduction (ITP) drugs, namely, Yannoyi's Reed Popa, Novartis's Aiqupopa, Amgen's Romispavilion and Sansheng Pharmaceutical's Tebiao, domestic declaration companies in the research sector include Qilu Pharmaceutical (Phase III), Hengrui (Haiquupa III) and Colum .
7 EGFR EGFR, is a transmembrane receptor associated with a variety of signaling pathways such as cell proliferation, metastasis and apoptosis The positive rate of EGFR gene sensitive mutation in patients with lung adenocarcinoma in China is about 50% Mutations or overexpression of EGFR are associated with tumor production, and studies have found high or abnormal egfrons of EGFR in many solid tumors The most prominent anti-tumor treatment for EGFR target research is the anti-tumor treatment of lung cancer domestic Fuhong Hanxuan, Koren, Lepu Bio, Tianlis, Baili Pharmaceuticals, Dingfu Target, XinWeishengco, Shore-Mai Bio, Zhaohua Biological have been conducted or approved to carry out eGFR antibody drug clinical trials in the past three years, Collum Pharmaceuticals has achieved 41 generic drugs continuously approved for market, 16 varieties through consistency evaluation, 2 varieties of innovative drugs to carry out clinical studies in China and the United States, a new generation of tumor immunology drug A293 approved clinical, the first innovative drug A167 completed the key phase II clinical efficacy assessment As of the end of January, Collum Pharmaceuticals had the highest number of patent applications at 317 companies in the pharmaceutical biobank Jiman Biotech (Shanghai) Co., Ltd., is a professional in biotechnology cutting-edge technology research and development of high-tech enterprises Since its establishment for 9 years has been committed to the development of slow virus and the construction of stable cell line based on slow virus method, has a variety of spot expression and functional cell lines, such as: CLDN18.2
expresscell line, TGF-beta reporter HEK-293 functional cell line, H_IL12 Reporter 293 Functional cell lines, ADCC Fc RIIa (158V) Jurkat Effector functional cell line, ADCP Fc RIIa (131H) Jurkat GFP Effector functional cell line, etc., while providing a wide range of expression and functional cell line custom service .